ARCHIVES

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

This article is from The Cancer Letter archive.

Vol. 26 No. 13 | March 31, 2000

Download PDF Visit The Full Archive

Related Articles

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001

“Long Overdue” Efforts By States Urged To Help Fund Community, Regional Cancer Control Efforts

August 4, 1978

ODAC Rejects Amsacrine NDA, Renews Idarubicin

September 14, 1990

ASCO Explores White, Minority Cancer Problem

July 13, 1990

HHS Says NIH Improperly Used Program For Scientists To Hire Administrators.

July 13, 2001

New Screening Tool Helps GP ID Hereditary BC Risk

October 27, 2006